Search

Your search keyword '"Suárez-Lledó, María"' showing total 238 results
Start Over Author "Suárez-Lledó, María"
238 results on '"Suárez-Lledó, María"'

1. Safety and efficacy of G-CSF after allogeneic hematopoietic cell transplantation using post-transplant cyclophosphamide: clinical and in vitro examination of endothelial activation

Author

Escribano-Serrat, Silvia, Pedraza, Alexandra, Suárez-Lledó, María, Charry, Paola, De Moner, Blanca, Martinez-Sanchez, Julia, Ramos, Alex, Ventosa-Capell, Helena, Moreno, Cristina, Guardia, Laia, Monge-Escartín, Inés, Riu, Gisela, Carcelero, Esther, Cid, Joan, Lozano, Miquel, Gómez, Pilar, García, Estefanía, Martín, Lidia, Carreras, Enric, Fernández-Avilés, Francesc, Martínez, Carmen, Rovira, Montserrat, Salas, María Queralt, and Díaz-Ricart, Maribel

Published
2024
Full Text
View/download PDF

3. EASIX and cardiac adverse events after allogeneic hematopoietic cell transplantation

Author

Tolosa-Ridao, Carles, Cascos, Enric, Rodríguez-Lobato, Luis Gerardo, Pedraza, Alexandra, Suárez-Lledó, María, Charry, Paola, Solano, María Teresa, Martinez-Sanchez, Julia, Cid, Joan, Lozano, Miquel, Rosiñol, Laura, Esteve, Jordi, Urbano-Ispizua, Álvaro, Fernández-Avilés, Francesc, Martínez, Carmen, Carreras, Enric, Díaz-Ricart, Maribel, Rovira, Montserrat, and Salas, María Queralt

Published
2024
Full Text
View/download PDF

4. Allogeneic hematopoietic cell transplantation with sequential conditioning regimen in relapsed refractory acute myeloid leukemia

Author

Tolosa-Ridao, Carles, Suárez-Lledó, María, Jiménez-Vicente, Carlos, Cortés-Bullich, Albert, Merchan, Beatriz, Martínez-Roca, Alexandra, Guijarro, Francisca, Castaño-Díez, Sandra, Rosiñol, Laura, Fernández-Avilés, Francesc, Martínez, Carmen, Díaz-Beya, Marina, Esteve, Jordi, Rovira, Montserrat, and Salas, María Queralt

Published
2024
Full Text
View/download PDF

8. Increased Serum Levels of N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) in Mobilized Healthy Donors with G-CSF: A Cohort Study

Author

Cid, Joan, Guinetti-Ortiz, Katia, Charry, Paola, Carbassé, Gloria, de Pablo-Miró, Mar, Rubia, Laura, Garcia, Marta, Alcaraz-Quiles, Jose, Cascos, Enric, Martínez-Cibrian, Nuria, Salas, María Queralt, Suárez-Lledó, Maria, Rosiñol, Laura, Fernández-Avilés, Francesc, Martínez, Carmen, Rovira, Montserrat, and Lozano, Miquel

Published
2024
Full Text
View/download PDF

9. Endothelial Activation and Stress Index in adults undergoing allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based prophylaxis

Author

Escribano-Serrat, Silvia, Rodríguez-Lobato, Luis Gerardo, Charry, Paola, Martínez-Cibrian, Nuria, Suárez-Lledó, María, Rivero, Andrea, Moreno-Castaño, Ana Belén, Solano, María Teresa, Arcarons, Jordi, Nomdedeu, Meritxell, Cid, Joan, Lozano, Miquel, Pedraza, Alexandra, Rosiñol, Laura, Esteve, Jordi, Urbano-Ispizua, Álvaro, Palomo, Marta, Fernández-Avilés, Francesc, Martínez, Carmen, Díaz-Ricart, Maribel, Carreras, Enric, Rovira, Montserrat, and Salas, María Queralt

Published
2024
Full Text
View/download PDF

10. Incidence, risk factors, and impact of early cardiac toxicity after allogeneic hematopoietic cell transplant

Author

Pérez-Valencia, Amanda Isabel, Cascos, Enric, Carbonell-Ordeig, Sara, Charry, Paola, Gómez-Hernando, Marta, Rodríguez-Lobato, Luis Gerardo, Suárez-Lledó, María, Martínez-Cibrian, Nuria, Antelo, María Gabriela, Solano, María Teresa, Arcarons, Jordi, Nomdedeu, Meritxell, Cid, Joan, Lozano, Miquel, Díaz-Ricart, Maribel, Rosiñol, Laura, Esteve, Jordi, Urbano-Ispizua, Álvaro, Carreras, Enric, Martínez, Carmen, Fernández-Avilés, Francesc, Rovira, Montserrat, and Salas, María Queralt

Published
2023
Full Text
View/download PDF

11. Applicability and validation of different prognostic scores in allogeneic hematopoietic cell transplant (HCT) in the post-transplant cyclophosphamide era

Author

Salas, María Queralt, Rodríguez-Lobato, Luis Gerardo, Charry, Paola, Suárez-Lledó, Maria, Pedraza, Alexandra, Solano, María Teresa, Arcarons, Jordi, Cid, Joan, Lozano, Miquel, Rosiñol, Laura, Esteve, Jordi, Carreras, Enric, Fernández-Avilés, Francesc, Martínez, Carmen, and Rovira, Montserrat

Published
2023
Full Text
View/download PDF

12. Real-World Experience with Isavuconazole in Allogeneic Stem Cell Transplantation in Spain

Author

Kwon, Mi, Gómez-Centurión, Ignacio, Oarbeascoa, Gillen, Torres, Melissa, Martinez, Ariadna Perez, Suarez-Lledó, Maria, Chinea, Anabelle, Cascón, Maria Jesus Pascual, Vazquez, Lourdes, Espigado, Ildefonso, Izquierdo, Isabel, Parody, Rocio, Cadenas, Irene Garcia, Calbacho, Maria, Sierra, Pedro Gonzalez, Heras, Inmaculada, Yañez, Lucrecia, Torrent, Anna, Bautista, Guiomar, Gonzalez, Soledad, Roldan, Elisa, Vallejo, Juan Carlos, Bailen, Rebeca, Borrero, Asunción, Lopez-Jiménez, Javier, Casas, Maria Angeles Cuesta, and Solano, Carlos

Published
2024
Full Text
View/download PDF

13. Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan

Author

Guijarro, Francesca, Bataller, Alex, Diaz-Beyá, Marina, Garrido, Ana, Coll-Ferrà, Christelle, Vives, Susana, Salamero, Olga, Valcárcel, David, Tormo, Mar, Arnan, Montserrat, Sampol, Antònia, Castaño-Díez, Sandra, Martínez, Carmen, Suárez-Lledó, María, Fernández-Avilés, Francesc, Hernández-Boluda, Juan Carlos, Ribera, Josep Maria, Rovira, Montserrat, Brunet, Salut, Sierra, Jorge, and Esteve, Jordi

Published
2022
Full Text
View/download PDF

15. Outcomes of older adults undergoing allogeneic hematopoietic cell transplantation with post‐transplant cyclophosphamide based prophylaxis.

Author

Murillo, Victoria, Charry, Paola, Suárez‐Lledó, María, Guardia, Laia, Moreno, Cristina, Cid, Joan, Lozano, Miquel, Pedraza, Alexandra, Salinas, Raquel, Vilas, Vanessa, Duch, Montserrat, Díaz‐Beya, Marina, Rosiñol, Laura, Esteve, Jordi, Carreras, Enric, Fernández‐Avilés, Francesc, Martínez, Carmen, Rovira, Montserrat, and Salas, María Queralt

Subjects
HEMATOPOIETIC stem cell transplantation, OLDER people, OLDER patients, CELL transplantation, OVERALL survival
Abstract

This study evaluates the feasibility of using post‐transplant cyclophosphamide (PTCY) prophylaxis in allo‐hematopoietic cell transplantation (HCT) for adults aged 65 and older. PTCY is increasingly used to prevent graft‐versus‐host disease (GVHD) across all donor types, but concerns remain about potential risks, especially in older patients. Fifty‐seven adults aged 65 or older with hematological malignancies, undergoing their first allo‐HCT with PTCY prophylaxis between January 2011 and January 2023 were included. Overall, 94.8% of patients achieved primary engraftment. The median durations for neutrophil and platelet engraftments were 19 and 21 days. The day +30 cumulative incidence of bacterial bloodstream infection was 43.9%. No CMV reactivations occurred within the first 100 days after letermovir implementation. The day +180 cumulative incidences of grade II–IV and III–IV acute GVHD, and the 2‐year cumulative incidence of moderate/severe chronic GVHD were 26.3%, 10.5%, and 4.8%. Eighteen patients (31.6%) relapsed, and 30 (52.6%) died, with relapse (16.4%) and infection (11.5%) being the main causes of death. The estimated 2‐year overall survival, non‐relapse mortality, cumulative incidence of relapse, and GVHD‐free relapse‐free survival rates were 45.5%, 27.1%, 33.9%, and 37.0%. Adults aged 70 or older had similar outcomes to those aged 65–69. This study confirms the safety and feasibility of PTCY‐based allo‐HCT in older adults. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Cyclophosphamide-free Mobilisation Increases Safety While Preserving the Efficacy of Autologous Haematopoietic Stem Cell Transplantation in Refractory Crohn's Disease Patients.

Author

Giordano, Antonio, Rovira, Montserrat, Veny, Marisol, Barastegui, Rebeca, Marín, Pedro, Martínez, Carmen, Fernández-Avilés, Francesc, Suárez-Lledó, María, Domènech, Ariadna, Serrahima, Anna, Lozano, Miquel, Cid, Joan, Ordás, Ingrid, Fernández-Clotet, Agnés, Caballol, Berta, Gallego, Marta, Vara, Alejandro, Masamunt, Maria Carme, Giner, Àngel, and Teubel, Iris

Abstract

Background and Aim Autologous haematopoietic stem cell transplantation [AHSCT] is a therapeutic option for refractory Crohn's disease [CD]. However, high adverse event rates related to chemotherapy toxicity and immunosuppression limit its applicability. This study aims to evaluate AHSCT's safety and efficacy using a cyclophosphamide [Cy]-free mobilisation regimen. Methods A prospective, observational study included 14 refractory CD patients undergoing AHSCT between June 2017 and October 2022. The protocol involved outpatient mobilisation with G-CSF 12–16 μg/kg/daily for 5 days, and optional Plerixafor 240 μg/d [1–2 doses] if the CD34 + cell count target was unmet. Standard conditioning with Cy and anti-thymocyte globulin was administered. Clinical, endoscopic, and radiological assessments were conducted at baseline and during follow-up. Results All patients achieved successful outpatient mobilisation [seven patients needed Plerixafor] and underwent transplantation. Median follow-up was 106 weeks (interquartile range [IQR] 52–348). No mobilisation-related serious adverse events [SAEs] or CD worsening occurred. Clinical and endoscopic remission rates were 71% and 41.7% at 26 weeks, 64% and 25% at 52 weeks, and 71% and 16.7% at the last follow-up, respectively. The percentage of patients who restarted CD therapy for clinical relapse and/or endoscopic/radiological activity was 14% at 26 weeks, 57% at 52 weeks, and 86% at the last follow-up, respectively. Peripheral blood cell populations and antibody levels post-AHSCT were comparable to Cy-based mobilisation. Conclusions Cy-free mobilisation is safe and feasible in refractory CD patients undergoing AHSCT. Although relapse occurs in a significant proportion of patients, clinical and endoscopic responses are achieved upon CD-specific therapy reintroduction. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Effects of CYP3A5 Genotype on Tacrolimus Pharmacokinetics and Graft-versus-Host Disease Incidence in Allogeneic Hematopoietic Stem Cell Transplantation

Author

Marco, Daniel N., primary, Molina, Mònica, additional, Guio, Ana-María, additional, Julian, Judit, additional, Fortuna, Virginia, additional, Fabregat-Zaragoza, Virginia-Lucila, additional, Salas, María-Queralt, additional, Monge-Escartín, Inés, additional, Riu-Viladoms, Gisela, additional, Carcelero, Esther, additional, Roma, Joan Ramón, additional, Llobet, Noemí, additional, Arcarons, Jordi, additional, Suárez-Lledó, María, additional, Rosiñol, Laura, additional, Fernández-Avilés, Francesc, additional, Rovira, Montserrat, additional, Brunet, Mercè, additional, and Martínez, Carmen, additional

Published
2024
Full Text
View/download PDF

18. Post-Transplantation Cyclophosphamide and Tacrolimus for Graft-versus-Host Disease Prevention after Allogeneic Hematopoietic Cell Transplantation from HLA-Matched Donors Has More Advantages Than Limitations

Author

Salas, María Queralt, Pedraza, Alexandra, Charry, Paola, Suárez-Lledó, María, Rodríguez-Lobato, Luis Gerardo, Brusosa, Marc, Solano, María Teresa, Serrahima, Anna, Nomdedeu, Meritxell, Cid, Joan, Lozano, Miquel, Arcarons, Jordi, de Llobet, Noemi, Rosiñol, Laura, Esteve, Jordi, Urbano-Ispizua, Álvaro, Carreras, Enric, Fernández-Avilés, Francesc, Rovira, Montserrat, and Martinez, Carmen

Published
2024
Full Text
View/download PDF

19. Easix Score Correlates With Endothelial Dysfunction Biomarkers and Predicts Risk of Acute Graft-Versus-Host Disease After Allogeneic Transplantation

Author

Pedraza, Alexandra, Salas, María Queralt, Rodríguez-Lobato, Luis Gerardo, Escribano-Serrat, Silvia, Suárez-Lledo, María, Martínez-Cebrian, Nuria, Solano, María Teresa, Arcarons, Jordi, Rosiñol, Laura, Gutiérrez-García, Gonzalo, Fernández-Avilés, Francesc, Moreno-Castaño, Ana Belén, Molina, Patricia, Pino, Marc, Carreras, Enric, Díaz-Ricart, Maribel, Rovira, Montserrat, Palomo, Marta, and Martínez, Carmen

Published
2024
Full Text
View/download PDF

20. Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group

Author

Solano, Carlos, Vázquez, Lourdes, Giménez, Estela, de la Cámara, Rafael, Albert, Eliseo, Rovira, Montserrat, Espigado, Ildefonso, Calvo, Carmen M., López-Jiménez, Javier, Suárez-Lledó, María, Chinea, Anabella, Esquirol, Albert, Pérez, Ariadna, Bermúdez, Aránzazu, Saldaña, Raquel, Heras, Inmaculada, González-Huerta, Ana J., Torrado, Tamara, Bautista, Guiomar, Batlle, Montserrat, Jiménez, Santiago, Vallejo, Carlos, Barba, Pere, Cuesta, María Á., Piñana, José L., and Navarro, David

Published
2021
Full Text
View/download PDF

21. Reduced Dose of Post-Transplant Cyclophosphamide with Tacrolimus for the Prevention of Graft-versus-Host Disease in HLA-Matched Donor Peripheral Blood Stem Cell Transplants: A Prospective Pilot Study.

Author

Juárez, Alex, Salas, María Queralt, Pedraza, Alexandra, Suárez-Lledó, María, Rodríguez-Lobato, Luís Gerardo, Solano, María Teresa, Serrahima, Anna, Nomdedeu, Meritxell, Cid, Joan, Lozano, Miquel, Charry, Paola, Arcarons, Jordi, Llobet, Noemí, Rosiñol, Laura, Fernández-Avilés, Francesc, Rovira, Montserrat, and Martínez, Carmen

Subjects
THERAPEUTIC use of antineoplastic agents, GRAFT versus host disease, HEMATOPOIETIC stem cell transplantation, DRUG toxicity, MYCOSES, TRANSPLANTATION of organs, tissues, etc., DRUG therapy, PILOT projects, NEUTROPHILS, BLOODBORNE infections, CATHETER-related infections, CYSTITIS, CYTOMEGALOVIRUS diseases, MAJOR adverse cardiovascular events, BLOOD transfusion reaction, HEMORRHAGIC diseases, DESCRIPTIVE statistics, DOSE-effect relationship in pharmacology, LONGITUDINAL method, BLOOD platelets, TACROLIMUS, DRUG efficacy, HERPESVIRUS diseases, PROGRESSION-free survival, CYCLOPHOSPHAMIDE, HLA-B27 antigen, OVERALL survival, IMMUNOSUPPRESSION, EVALUATION, DISEASE risk factors
Abstract

Simple Summary: High-dose post-transplant cyclophosphamide is effective in preventing graft-versus-host disease (GVHD) but is associated with adverse outcomes such as delayed engraftment, infections, and cardiac issues. This pilot study evaluated the efficacy and toxicity of reduced-dose PTCY (40 mg/kg/day) in patients undergoing HLA-matched allogeneic hematopoietic stem cell transplantation (alloHSCT). Neutrophil and platelet engraftment occurred at medians of 15 and 16 days, respectively. At day 100, the incidences of grade II–IV and III–IV acute GVHD were 18.2% and 4.5%, respectively, with no cases of grade IV acute GVHD or steroid-refractory disease. One-year incidence of moderate-severe chronic GVHD was 6.4%. Both incidences, acute GVHD and chronic GVHD, are similar to our previous experience with higher doses of PTCY. Two-year overall survival and relapse-free survival were 77.1% and 58.3%. There were low incidences of infections and only one early cardiac event. These results suggest that reduced-dose PTCY provides adequate immunosuppression with a low toxicity profile. PTCY 50 mg/kg/day on days +3/+4 is an excellent strategy to prevent GVHD. However, its use is associated with adverse outcomes such as delayed engraftment, increased risk of infection, and cardiac complications. This pilot study evaluates the efficacy and toxicity of a reduced dose of PTCY (40 mg/kg/day) combined with tacrolimus in 22 peripheral blood HLA-matched alloHSCT patients. At day +100, the cumulative incidences of grade II–IV and III–IV acute GVHD were 18.2% and 4.5%, respectively. No grade IV acute GVHD or steroid-refractory disease was observed. The cumulative incidences of all-grade and moderate-severe chronic GVHD at 1-year were 11.4% and 6.4%, respectively. No patient died from transplant-related complications. Two-year OS and RFS were 77.1% and 58.3%, respectively. All patients engrafted, with neutrophil and platelet recovery occurring at a median of 15 (IQR 14–16) and 16 days (IQR 12–23), respectively. The cumulative incidences of bloodstream bacterial infections, polyomavirus BK hemorrhagic cystitis, HHV6 reactivation, CMV reactivation, and fungal infections were 13.6%, 9.1%, 9.1%, 4.6%, and 6%, respectively. Only one early cardiac event was observed. These results suggest that PTCY 40 mg/kg/day on a +3/+4 schedule provides adequate immunosuppression to allow for engraftment and prevent clinically significant GVHD with a low toxicity profile. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group.

Author

Jiménez‐Vicente, Carlos, Charry, Paola, Castaño‐Diez, Sandra, Guijarro, Francesca, López‐Guerra, Mònica, Pérez‐Valencia, Amanda Isabel, Martinez‐Roca, Alexandra, Cortés‐Bullich, Albert, Munárriz, Daniel, Solano, Maria Teresa, Rosiñol, Laura, Carreras, Enric, Urbano‐Ispizua, Álvaro, Fernández‐Avilés, Francesc, Martinez, Carmen, Suárez‐Lledó, María, Díaz‐Beyá, Marina, Rovira, Montserrat, Salas, María Queralt, and Esteve, Jordi

Subjects
HEMATOPOIETIC stem cell transplantation, ACUTE myeloid leukemia, ALLOIMMUNITY, GRAFT versus host reaction, CELL transplantation
Abstract

Summary: European LeukemiaNet refined their risk classification of acute myeloid leukaemia (AML) in 2022 (ELN 2022) according to the two new myeloid classifications published the same year. We have retrospectively assessed the prognostic value of the ELN 2022 in 120 AML patients undergoing allogeneic haematopoietic cell transplantation (allo‐HCT), including 99 in first complete response (CR1) from 2011 to 2021 in our centre. Adverse risk patients (Adv) presented inferior outcome in terms of overall survival (OS) and leukaemia‐free survival (LFS) (OS [p = 0.003], LFS [p = 0.02]), confirmed in multivariate analysis (hazard ratio [HR] for OS = 2.00, p = 0.037). These results were also seen in patients allografted in CR1. Further analysis identified a subgroup named adverse‐plus (AdvP), including complex karyotype, MECOM(EVI1) rearrangements and TP53 mutations, with worse outcomes than the rest of groups of patients, including the Adv (HR for OS: 3.14, p < 0.001, HR for LFS: 3.36, p < 0.001), with higher 2‐year cumulative incidence of relapse (p < 0.001). Notably, within this analysis, the outcome of Adv and intermediate patients were similar. These findings highlight the prognostic value of ELN 2022 in patients undergoing allo‐HCT, which can be improved by the recognition of a poor genetic subset (AdvP) within the Adv risk group. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with hematological malignancies

Author

Gudiol, Carlota, Aguilar-Guisado, Manuela, Azanza, José Ramón, Candel, Francisco Javier, Cantón, Rafael, Carratalà, Jordi, Garcia-Vidal, Carolina, Jarque, Isidro, Lizasoain, Manuel, Gil-Bermejo, José Molina, Ruiz-Camps, Isabel, Sánchez-Ortega, Isabel, Solano, Carlos, Suárez-Lledó, María, Vázquez, Lourdes, and de la Cámara, Rafael

Published
2020
Full Text
View/download PDF

25. Reduced Dose of Post-transplant Cyclophosphamide with Tacrolimus for the Prevention of Graft-versus-Host Disease in HLA-Matched Donor Peripheral Blood Stem Cell Transplants: A Prospective Pilot Study

Author

Martinez, Carmen, primary, Juárez, Alex, additional, Salas, María Queralt, additional, Pedraza, Alexandra, additional, Suárez-Lledó, María, additional, Rodríguez-Lobato, Luis Gerardo, additional, Solano, María, additional, Serrahima, Anna, additional, Nomdedeu, Meritxell, additional, Cid, Joan, additional, Lozano, Miquel, additional, Charry, Paola, additional, Arcarons, Jordi, additional, de Llobet, Noemí, additional, Rosiñol, Laura, additional, Fernández-Avilés, Francesc, additional, and Rovira, Montse, additional

Published
2024
Full Text
View/download PDF

26. Impact of severe acute kidney injury and chronic kidney disease on allogeneic hematopoietic cell transplant recipients: a retrospective single center analysis

Author

Gutiérrez-García, Gonzalo, Villarreal, Jesús, Garrote, Marta, Rovira, Montserrat, Blasco, Miquel, Suárez-Lledó, María, Rodríguez-Lobato, Luis Gerardo, Charry, Paola, Rosiñol, Laura, Marín, Pedro, Pedraza, Alexandra, Solano, María Teresa, Ramos, Carla, de Llobet, Noemí, Lozano, Miquel, Cid, Joan, Martínez, Carmen, Poch, Esteban, Carreras, Enric, Urbano-Ispizua, Álvaro, Fernández-Avilés, Francesc, Pereira, A., and Quintana, Luis F.

Published
2020
Full Text
View/download PDF

27. A reproducible and safe at-home allogeneic haematopoietic cell transplant program: first experience in Central and Southern Europe

Author

Gutiérrez-García, Gonzalo, Rovira, Montserrat, Arab, Nacira, Gallego, Cristina, Sánchez, Joan, Ángeles Álvarez, María, Ayora, Pilar, Domenech, Ariadna, Borràs, Nuria, Gerardo Rodríguez-Lobato, Luis, Rosiñol, Laura, Marín, Pedro, Pedraza, Alexandra, Martínez-Roca, Alexandra, Carcelero, Esther, Dolores Herrera, María, Teresa Solano, María, Ramos, Carla, de Llobet, Noemí, Serrahima, Anna, Lozano, Miquel, Cid, Joan, Martínez, Carmen, Suárez-Lledó, María, Urbano-Ispizua, Álvaro, and Fernández-Avilés, Francesc

Published
2020
Full Text
View/download PDF

28. Quantitative PCR Is Faster, More Objective, and More Reliable Than Immunohistochemistry for the Diagnosis of Cytomegalovirus Gastrointestinal Disease in Allogeneic Stem Cell Transplantation

Author

Suárez-Lledó, María, Marcos, Maria Ángeles, Cuatrecasas, Miriam, Bombi, Josep Antoni, Fernández-Avilés, Francesc, Magnano, Laura, Martínez-Cibrián, Núria, Llobet, Noemi, Rosiñol, Laura, Gutiérrez-García, Gonzalo, Jorge, Sofía, Martínez, Carmen, Rovira, Montserrat, and Urbano-Ispizua, Álvaro

Published
2019
Full Text
View/download PDF

29. At-Home Foscarnet Administration in Patients with Cytomegalovirus Infection Post-Allogeneic Stem Cell Transplantation: A Unicentric, Safe, and Feasible Program

Author

Ruiz-Boy, Sonia, primary, Pedraza, Alexandra, additional, Prat, Marta, additional, Salas, Maria Queralt, additional, Carcelero, Esther, additional, Riu-Viladoms, Gisela, additional, Suárez-Lledó, María, additional, Monge-Escartín, Inés, additional, Rodríguez-Lobato, Luis Gerardo, additional, Martínez-Roca, Alexandra, additional, Rovira, Montserrat, additional, Martínez, Carmen, additional, Gallego, Cristina, additional, Urbano-Ispizua, Álvaro, additional, Sánchez, Joan, additional, Marcos, María Ángeles, additional, and Fernández-Avilés, Francesc, additional

Published
2023
Full Text
View/download PDF

30. Impact of letermovir prophylaxis in CMV reactivation and disease after allogenic hematopoietic cell transplantation: a real-world, observational study

Author

Brusosa, Marc, primary, Ruiz, Sonia, additional, Monge, Inés, additional, Solano, María Teresa, additional, Rosiñol, Laura, additional, Esteve, Jordi, additional, Carreras, Enric, additional, Marcos, M. Ángeles, additional, Riu, Gisela, additional, Carcelero, Esther, additional, Martinez, Carmen, additional, Fernández-Avilés, Francesc, additional, Rovira, Montserrat, additional, Suárez-Lledó, María, additional, and Salas, María Queralt, additional

Published
2023
Full Text
View/download PDF

31. Endothelial Activation and Stress Index in adults undergoing allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based prophylaxis

Author

Escribano-Serrat, Silvia, primary, Rodríguez-Lobato, Luis Gerardo, additional, Charry, Paola, additional, Martínez-Cibrian, Nuria, additional, Suárez-Lledó, María, additional, Rivero, Andrea, additional, Moreno-Castaño, Ana Belén, additional, Solano, María Teresa, additional, Arcarons, Jordi, additional, Nomdedeu, Meritxell, additional, Cid, Joan, additional, Lozano, Miquel, additional, Pedraza, Alexandra, additional, Rosiñol, Laura, additional, Esteve, Jordi, additional, Urbano-Ispizua, Álvaro, additional, Palomo, Marta, additional, Fernández-Avilés, Francesc, additional, Martínez, Carmen, additional, Díaz-Ricart, Maribel, additional, Carreras, Enric, additional, Rovira, Montserrat, additional, and Salas, María Queralt, additional

Published
2023
Full Text
View/download PDF

32. Bacterial Bloodstream Infections in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

Author

Salas, María Queralt, Charry, Paola, Puerta-Alcalde, Pedro, Martínez-Cibrian, Nuria, Solano, María Teresa, Serrahima, Ana, Nomdedeu, Meritxell, Cid, Joan, Lozano, Miquel, Chumbinta, Mariana, Aiello, Tommaso Francesco, Arcarons, Jordi, LLobet, Noemi de, Pedraza, Alexandra, Rosiñol, Laura, Esteve, Jordi, Urbano-Ispizua, Álvaro, Carreras, Enric, Martínez, Carmen, Fernández-Avilés, Francesc, García-Vidal, Carolina, Suárez-Lledó, Maria, and Rovira, Monserrat

Published
2022
Full Text
View/download PDF

33. PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT

Author

Salas, María Queralt, Charry, Paola, Pedraza, Alexandra, Martínez-Cibrian, Nuria, Solano, María Teresa, Domènech, Ariadna, Suárez-Lledó, Maria, Nomdedeu, Meritxell, Cid, Joan, Lozano, Miquel, de-LLobet, Noemi, Arcarons, Jordi, Rosiñol, Laura, Gutiérrez-García, Gonzalo, Carreras, Enric, Esteve, Jordi, Urbano-Ispizua, Álvaro, Fernández-Avilés, Francesc, Rovira, Montserrat, and Martínez, Carmen

Published
2022
Full Text
View/download PDF

34. Deleterious Effect of Steroids on Cytomegalovirus Infection Rate after Allogeneic Stem Cell Transplantation Depends on Pretransplant Cytomegalovirus Serostatus of Donors and Recipients

Author

Suárez-Lledó, María, Martínez-Cibrián, Núria, Gutiérrez-García, Gonzalo, Dimova-Svetoslavova, Veselka, Marcos, Ma Angeles, Martín-Antonio, Beatriz, Martínez-Trillos, Alejandra, Villamor, Neus, Rosiñol, Laura, Martínez, Carmen, Fernández-Avilés, Francesc, García-Vidal, Carolina, Urbano-Ispizua, Álvaro, and Rovira, Montserrat

Published
2018
Full Text
View/download PDF

36. Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis

Author

Gutiérrez-García, Gonzalo, Cibeira, María Teresa, Rovira, Montserrat, Fernández de Larrea, Carlos, Tovar, Natalia, Rodríguez-Lobato, Luis Gerardo, Rosiñol, Laura, Marín, Pedro, Solano-Vega, Julio, Suárez-Lledó, María, Bataller, Alex, Solano, María Teresa, de Llobet, Noemí, Domenech, Ariadna, Borràs, Nuria, Lozano, Miquel, Cid, Joan, Martínez, Carmen, Urbano-Ispizua, Álvaro, Esteve, Jordi, Carreras, Enric, Fernández-Avilés, Francesc, and Bladé, Joan

Published
2019
Full Text
View/download PDF

38. Risk Factors for Mortality in Hematopoietic Stem Cell Transplantation Recipients with Bloodstream Infection: Points To Be Addressed by Future Guidelines

Author

Puerta-Alcalde, Pedro, Chumbita, Mariana, Charry, Paola, Castaño-Díez, Sandra, Cardozo, Celia, Moreno-García, Estela, Marco, Francesc, Suárez-Lledó, Maria, Garcia-Pouton, Nicole, Morata, Laura, Fernández-Avilés, Francesc, Martínez-Roca, Alexandra, Rodríguez, Gerardo, Martínez, Jose A., Martínez, Carmen, Mensa, Josep, Urbano, Álvaro, Rovira, Montserrat, Soriano, Alex, and Garcia-Vidal, Carolina

Published
2021
Full Text
View/download PDF

39. Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation

Author

Gutiérrez-García, Gonzalo, Rovira, Montserrat, Magnano, Laura, Rosiñol, Laura, Bataller, Alex, Suárez-Lledó, María, Cibeira, María Teresa, de Larrea, Carlos Fernández, Garrote, Marta, Jorge, Sofia, Moreno, Ana, Rodríguez-Lobato, Luis Gerardo, Carreras, Enric, Díaz-Ricart, Maribel, Palomo, Marta, Martínez, Carmen, Urbano-Ispizua, Alvaro, Bladé, Joan, and Fernández-Avilés, Francesc

Published
2018
Full Text
View/download PDF

40. Current outcomes of SARS-CoV-2 Omicron variant infection in high-risk haematological patients treated early with antivirals

Author

Aiello, Tommaso-Francesco, primary, Puerta-Alcalde, Pedro, additional, Chumbita, Mariana, additional, Lopera, Carlos, additional, Monzó, Patricia, additional, Cortes, Albert, additional, Fernández-Avilés, Francesc, additional, Suárez-Lledó, María, additional, Correa, Juan, additional, Ortiz-Maldonado, Valentín, additional, Cuesta, Genoveva, additional, Martinez-Cibrian, Nuria, additional, Esteve, Jordi, additional, Marcos, Maria Ángeles, additional, Mensa, Josep, additional, Soriano, Alex, additional, and Garcia-Vidal, Carolina, additional

Published
2023
Full Text
View/download PDF

42. Post-mortem neuropathologic examination of a 5-case series of CAR T-cell treated patients

Author

Vidal Robau, Núria, Caballero, Gabriela, Archilla, Ivan, Ladino, Andrea, Fernández, Sara, Ortiz-Maldonado, Valentín, Rovira, Montserrat, Gómez-Hernando, Marta, Delgado, Julio, Suárez-Lledó, María, Fernández De Larrea, Carlos, Balagué, Olga, Frigola, Gerard, Muñoz, Abel, Ortiz, Estrella, Ribalta, Teresa, Martinez, Miguel J., Angeles-Marcos, Maria, Español-Rego, Marta, González, Azucena, Benitez-Ribas, Daniel, Martinez-Hernandez, Eugenia, Castro, Pedro, and Aldecoa, Iban

Abstract

Introduction: Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapy for the treatment of refractory hematopoietic malignancies. Adverse events are common, and neurotoxicity is one of the most important. However, the physiopathology is unknown and neuropathologic information is scarce. Materials and methods: Post-mortem examination of 6 brains from patients that underwent CAR T-cell therapy from 2017 to 2022. In all cases, polymerase chain reaction (PCR) in paraffin blocks for the detection of CAR T cells was performed. Results: Two patients died of hematologic progression, while the others died of cytokine release syndrome, lung infection, encephalomyelitis, and acute liver failure. Two out of 6 presented neurological symptoms, one with extracranial malignancy progression and the other with encephalomyelitis. The neuropathology of the latter showed severe perivascular and interstitial lymphocytic infiltration, predominantly CD8+, together with a diffuse interstitial histiocytic infiltration, affecting mainly the spinal cord, midbrain, and hippocampus, and a diffuse gliosis of basal ganglia, hippocampus, and brainstem. Microbiological studies were negative for neurotropic viruses, and PCR failed to detect CAR T -cells. Another case without detectable neurological signs showed cortical and subcortical gliosis due to acute hypoxic-ischemic damage. The remaining 4 cases only showed a mild patchy gliosis and microglial activation, and CAR T cells were detected by PCR only in one of them. Conclusions: In this series of patients that died after CAR T-cell therapy, we predominantly found non-specific or minimal neuropathological changes. CAR T-cell related toxicity may not be the only cause of neurological symptoms, and the autopsy could detect additional pathological findings., Free Neuropathology, Bd. 3 (2022)

Published
2022
Full Text
View/download PDF

43. Post-mortem neuropathologic examination of a 6-case series of CAR T-cell treated patients

Author

Vidal-Robau, Nuria, Caballero, Gabriela, Archilla, Ivan, Ladino, Andrea, Fernández, Sara, Ortiz-Maldonado, Valentín, Rovira, Montserrat, Gómez-Hernando, Marta, Delgado, Julio, Suárez-Lledó, María, Fernández de Larrea, Carlos, Balagué, Olga, Frigola, Gerard, Muñoz, Abel, Ortiz, Estrella, Ribalta, Teresa, Martinez, Miguel J, Angeles-Marcos, Maria, Español-Rego, Marta, González, Azucena, Benitez-Ribas, Daniel, Martinez-Hernandez, Eugenia, Castro, Pedro, and Aldecoa, Iban

Subjects
Original Paper
Abstract

Introduction: Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapy for the treatment of refractory hematopoietic malignancies. Adverse events are common, and neurotoxicity is one of the most important. However, the physiopathology is unknown and neuropathologic information is scarce. Materials and methods: Post-mortem examination of 6 brains from patients that underwent CAR T-cell therapy from 2017 to 2022. In all cases, polymerase chain reaction (PCR) in paraffin blocks for the detection of CAR T cells was performed. Results: Two patients died of hematologic progression, while the others died of cytokine release syndrome, lung infection, encephalomyelitis, and acute liver failure. Two out of 6 presented neurological symptoms, one with extracranial malignancy progression and the other with encephalomyelitis. The neuropathology of the latter showed severe perivascular and interstitial lymphocytic infiltration, predominantly CD8+, together with a diffuse interstitial histiocytic infiltration, affecting mainly the spinal cord, midbrain, and hippocampus, and a diffuse gliosis of basal ganglia, hippocampus, and brainstem. Microbiological studies were negative for neurotropic viruses, and PCR failed to detect CAR T -cells. Another case without detectable neurological signs showed cortical and subcortical gliosis due to acute hypoxic-ischemic damage. The remaining 4 cases only showed a mild patchy gliosis and microglial activation, and CAR T cells were detected by PCR only in one of them. Conclusions: In this series of patients that died after CAR T-cell therapy, we predominantly found non-specific or minimal neuropathological changes. CAR T-cell related toxicity may not be the only cause of neurological symptoms, and the autopsy could detect additional pathological findings.

Published
2022

44. Impact of Early Intrapatient Variability of Tacrolimus Concentrations on the Risk of Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide

Author

Marco, Daniel N., primary, Salas, María Queralt, additional, Gutiérrez-García, Gonzalo, additional, Monge, Inés, additional, Riu, Gisela, additional, Carcelero, Esther, additional, Roma, Joan Ramón, additional, Llobet, Noemí, additional, Arcarons, Jordi, additional, Suárez-Lledó, María, additional, Martínez, Nuria, additional, Pedraza, Alexandra, additional, Domenech, Ariadna, additional, Rosiñol, Laura, additional, Fernández-Avilés, Francesc, additional, Urbano-Ispízua, Álvaro, additional, Rovira, Montserrat, additional, Brunet, Mercè, additional, and Martínez, Carmen, additional

Published
2022
Full Text
View/download PDF

45. Impact of Ptcy-Based Prophylaxis on Early Infectious Complications in Adults Undergoing Peripheral Blood Allo-HCT

Author

Salas, María Queralt, primary, Charry, Paola, additional, Puerta-Alcalde, Pedro, additional, Martínez-Cibrian, Nuria, additional, Chumbita, Mariana, additional, Aiello, Tommaso Francesco, additional, Brusosa, Marc, additional, Solano, María Teresa, additional, Serrahima, Anna, additional, Cid, Joan, additional, Lozano, Miquel, additional, Arcarons, Jordi, additional, Llobet, Noemí, additional, Rosinol Dachs, Laura, additional, Esteve, Jordi, additional, Urbano-Ispizua, Álvaro, additional, Carreras, Enric, additional, García-Vidal, Carolina, additional, Martinez Munoz, Maria Carmen, additional, Fernández-Avilés, Francesc, additional, Suárez-Lledó, María, additional, and Rovira, Montserrat, additional

Published
2022
Full Text
View/download PDF

46. Impressive Reduction of Gvhd Incidence Using Ptcy-TK for Gvhd Prevention in Adults Undergoing 10/10 HLA-Matched Peripheral Blood Allo-HCT

Author

Salas, María Queralt, primary, Charry, Paola, additional, Martínez-Cibrian, Nuria, additional, Suárez-Lledó, María, additional, Rodríguez-Lobato, Luis Gerardo, additional, Brusosa, Marc, additional, Solano, María Teresa, additional, Nomdedeu, Meritxell, additional, Cid, Joan, additional, Lozano, Miquel, additional, Arcarons, Jordi, additional, Llobet, Noemí, additional, Rosinol Dachs, Laura, additional, Esteve, Jordi, additional, Urbano-Ispizua, Álvaro, additional, Carreras, Enric, additional, Fernández-Avilés, Francesc, additional, Martinez Munoz, Maria Carmen, additional, and Rovira, Montserrat, additional

Published
2022
Full Text
View/download PDF

47. Viral-Specific T Cell Therapy for Cytomegalovirus Infection after Stem Cell Transplantation and Generation of a Third-Party T-Cell Donor Registry

Author

Barba, Pere, primary, Roldan, Elisa, additional, Suárez-Lledó, María, additional, Montoro Gomez, Juan, additional, Perez-Hoyos, Santiago, additional, Mussetti, Alberto, additional, Ferra, Christelle, additional, Coll, Ruth, additional, Rodriguez, Luciano, additional, Marsal, Julia, additional, Martino, Rodrigo, additional, Castaño, Julio, additional, Codinach, Marga, additional, Bosch, Francesc, additional, Gimeno, Ramon, additional, Valcarcel, David, additional, Rudilla, Francesc, additional, and Querol, Sergio, additional

Published
2022
Full Text
View/download PDF

48. Easix Application in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Prophylaxis

Author

Escribano Serrat, Silvia, primary, Charry, Paola, additional, Rodríguez-Lobato, Luis Gerardo, additional, Moreno-Castaño, Ana Belén, additional, Suárez-Lledó, María, additional, Martínez-Cibrian, Nuria, additional, Solano, María Teresa, additional, Arcarons, Jordi, additional, Nomdedeu, Meritxell, additional, Cid, Joan, additional, Lozano, Miquel, additional, Pedraza, Alexandra, additional, Rosiñol, Laura, additional, Esteve, Jordi, additional, Urbano-Ispizua, Álvaro, additional, Palomo, Marta, additional, Fernández-Avilés, Francesc, additional, Martinez Munoz, Maria Carmen, additional, Diaz-Ricart, Maribel, additional, Carreras, Enric, additional, Rovira, Montserrat, additional, and Salas, María Queralt, additional

Published
2022
Full Text
View/download PDF

50. Genotypic and Phenotypic Study of Antiviral Resistance Mutations in Refractory Cytomegalovirus Infection

Author

Hospital Clínic de Barcelona, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación (España), Agencia Estatal de Investigación (España), Ministerio de Economía y Competitividad (España), Fundació La Marató de TV3, Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (España), Generalitat de Catalunya, Santos, Marta [0000-0001-5270-4454], Alain, Sophie [0000-0002-9787-1421], Santos, Marta, Plault, Nicolas, Sánchez-Palomino, Sonsoles, Rodríguez-Sinovas, Cristina, Navarro Gabriel, Mireia, Mosquera, María Mar, Fernández-Avilés, Francisco, Suárez-Lledó, María, Rovira, Montserrat, Bodro, Marta, Moreno, Asunción, Linares, Laura, Cofan, Frederic, Berengua, Carla, Esteva, Cristina, Cordero, Elisa, Martín-Dávila, Pilar, Aranzamendi, Maitane, Pérez Jiménez, Ana Belén, Vidal, Elisa, Fernández Sabé, Nuria, Len, Oscar, Hantz, Sebastien, Alain, Sophie, Marcos, María Ángeles, Hospital Clínic de Barcelona, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación (España), Agencia Estatal de Investigación (España), Ministerio de Economía y Competitividad (España), Fundació La Marató de TV3, Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (España), Generalitat de Catalunya, Santos, Marta [0000-0001-5270-4454], Alain, Sophie [0000-0002-9787-1421], Santos, Marta, Plault, Nicolas, Sánchez-Palomino, Sonsoles, Rodríguez-Sinovas, Cristina, Navarro Gabriel, Mireia, Mosquera, María Mar, Fernández-Avilés, Francisco, Suárez-Lledó, María, Rovira, Montserrat, Bodro, Marta, Moreno, Asunción, Linares, Laura, Cofan, Frederic, Berengua, Carla, Esteva, Cristina, Cordero, Elisa, Martín-Dávila, Pilar, Aranzamendi, Maitane, Pérez Jiménez, Ana Belén, Vidal, Elisa, Fernández Sabé, Nuria, Len, Oscar, Hantz, Sebastien, Alain, Sophie, and Marcos, María Ángeles

Abstract

[Background] This study describes the genotypic and phenotypic characterization of novel human cytomegalovirus (HCMV) genetic variants of a cohort of 94 clinically resistant HCMV patients., [Methods and results] Antiviral-resistant mutations were detected in the UL97, UL54, and UL56 target genes of 25 of 94 (26.6%) patients. The genotype-phenotype correlation study resolved the status of 5 uncharacterized UL54 deoxyribonucleic acid polymerase (G441S, A543V, F460S, R512C, A928T) and 2 UL56 terminase (F345L, P800L) mutations found in clinical isolates. A928T conferred high, triple resistance to ganciclovir, foscarnet, and cidofovir, and A543V had 10-fold reduced susceptibility to cidofovir. Viral growth assays showed G441S, A543V, F345L, and P800L impaired viral growth capacities compared with wild-type AD169 HCMV. Three-dimensional modeling predicted A543V and A928T phenotypes but not R512C, reinforcing the need for individual characterization of mutations by recombinant phenotyping., [Conclusions] Extending mutation databases is crucial to optimize treatments and to improve the assessment of patients with resistant/refractory HCMV infection.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results